세계의 인간 혈소판 용해액(HPL) 시장 : 시장 규모, 점유율, 동향, 업계 분석(용도별, 유형별, 최종 용도별, 지역별), 예측(2025-2034년)
Human Platelet Lysate Market Size, Share, Trends, & Industry Analysis Report: By Application (Research and Therapeutic), By Type, By End Use, By Region - Market Forecast, 2025-2034
상품코드:1762564
리서치사:Polaris Market Research
발행일:2025년 06월
페이지 정보:영문 113 Pages
라이선스 & 가격 (부가세 별도)
한글목차
Polaris Market Research의 최신 조사에 따르면, 전 세계 인간 혈소판 용해액(HPL) 시장 규모는 2034년까지 7,848만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 향후 시장 성장에 대한 분석을 제공합니다.
인간 혈소판 용해액(HPL)은 생물 의학 연구 및 재생 의학 분야에서 매우 중요한 성분으로 등장하여 세포 배양 기술 및 치료 용도에 혁명을 일으키고 있습니다. 인간 혈소판에서 추출한 이 다재다능한 제품은 소 태아 혈청(FBS)과 같은 기존 세포 배양 보충제에 비해 많은 이점을 제공하며, HPL에 대한 수요 증가는 안전성, 효율성, 윤리적 고려 사항 등 여러 가지 요인에 기인합니다.
인간 혈소판 용해액(HPL) 시장은 과학의 발전과 실제 의료 수요에 의해 성장하고 있습니다. 세계 각국 정부는 자금 지원, 보조금, 규제적 지원을 통해 재생의료에 많은 투자를 하고 있습니다. 이러한 노력은 과학자들과 기업들이 인간 혈소판 용해액에 의존하여 세포를 안전하고 효과적으로 증식 및 증식시키는 새로운 치료법을 모색하는 데 힘을 실어주고 있습니다. 이러한 지원으로 이 분야에 대한 신뢰가 쌓여 줄기세포 치료법이 더 빠르게 발전할 수 있게 되었습니다. 또한, 파킨슨병, 골관절염, 탈모증(남성형 탈모증) 등 만성 질환 증가가 HPL 시장의 성장을 주도하고 있습니다. 이러한 질병은 인구의 고령화와 라이프스타일의 변화로 인해 더욱 보편화되고 있습니다. 현재 이러한 질환의 대부분은 치료 옵션이 제한적이기 때문에 의사와 연구자들은 재생의학으로 눈을 돌리고 있습니다. 혈소판 용해액은 손상된 조직을 복구하고 재생하는 데 도움이 되는 천연 성장 인자를 포함하고 있기 때문에 이러한 새로운 치료법에서 더 자주 사용되고 있습니다.
규제 환경은 HPL 시장의 성장에 기여하고 있습니다. 많은 국가의 규제 기관은 윤리적으로 조달된 안전한 세포 배양 보충제의 사용을 포함하여 보다 안전하고 투명한 연구 관행을 옹호하고 있습니다. 우수한 안전성과 윤리적 프로파일을 갖춘 HPL은 이러한 규제 요건을 충족하고 임상시험 및 치료 용도의 승인 절차를 용이하게 합니다.
인간 혈소판 용해액(HPL) 시장 : 분석 개요
유형별로는 헤파린 프리 기반 인간 혈소판 용해제 부문이 인간 혈소판 용해제 시장 점유율을 독점하고 있습니다. 이는 규제 준수, 안전성, 임상 및 연구 환경에서의 광범위한 적용성에서 유리하기 때문입니다. 헤파린을 함유하지 않은 HPL은 세포 배양 및 재생 의학에서 중요한 성분으로 부상하고 있으며, 기존의 성장 보조제를 대체할 수 있는 무혈청 대안으로 떠오르고 있습니다.
용도별로는 연구용 분야가 예측 기간 동안 3.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 빠른 성장은 세포 배양 연구에서 소 태아 혈청을 대체할 수 있는 우수한 대안으로 인간 혈소판 용해액의 사용이 증가하고 있기 때문입니다. 인간 혈소판 용해액은 중간엽 줄기세포, 면역세포 및 기타 인간 유래 세포의 증식에 필수적인 성장인자를 풍부하게 함유하고 있어 전임상 및 중개연구에 이상적입니다.
2024년 인간 혈소판 용해액(HPL) 시장의 매출 점유율은 북미가 압도적으로 높았습니다. 북미는 줄기세포 연구의 중심지로서, 형질전환 줄기세포, 유도만능줄기세포(iPSC), 성체줄기세포를 포함한 줄기세포 연구의 거점이며, HPL은 발생 과정 연구 및 치료 적용을 위해 이러한 세포를 배양하고 증식시키는 데 사용됩니다. 미국에서는 줄기세포 배양은 재생의료 및 생의학 연구 분야에서 기본 요소로 작용하고 있습니다.
유럽의 인간 혈소판 용해액(HPL) 시장은 이 지역이 생물의학 연구에 중점을 두고 있고, 재생의료 분야가 확대되고 있으며, 규제 환경이 양호한 만큼 큰 성장세를 보이고 있습니다.
세계 주요 시장 기업으로는 Merck KGaA, Compass Biomedical Inc, PL BioScience, AventaCell BioMedical Corp, Mill Creek Lifesciences LLC, Stem Cell Technologies Inc, Zen Bio, Inc, Sclavo Diagnostics International Sr, Lifescience Group Limited, Trinova Biochem GmbH 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 분석 방법
제4장 시장 인사이트
인간 혈소판 용해액 : 시장 현황
밸류체인 분석
인간 혈소판 용해액시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
대체품의 위협(저)
신규 진출업체의 위협(저-중)
바이어의 교섭력(중)
공급 기업의 교섭력(중-고)
경쟁 기업간 경쟁 관계(중-고)
PESTLE 분석
COVID-19의 영향 분석과 업계 동향
제5장 인간 혈소판 용해액시장 평가 : 유형별
서론
Heparin Based Human Platelet Lysate
Heparin Free Based Human Platelet Lysate
제6장 인간 혈소판 용해액시장 평가 : 용도별
서론
연구용
치료용
제7장 인간 혈소판 용해액시장 평가 : 최종사용자별
서론
제약 기업 및 바이오테크놀러지 기업
학술연구기관
기타
제8장 인간 혈소판 용해액시장 분석 : 지역별
서론
북미
북미의 인간 혈소판 용해액시장 : 유형별
북미의 인간 혈소판 용해액시장 : 용도별
최종사용자별
미국
캐나다
유럽
유럽의 인간 혈소판 용해액시장 : 유형별
유럽의 인간 혈소판 용해액시장 : 용도별
최종사용자별
프랑스
독일
영국
이탈리아
네덜란드
스페인
러시아
기타 유럽
아시아태평양
아시아태평양의 인간 혈소판 용해액시장 : 유형별
아시아태평양의 인간 혈소판 용해액시장 : 용도별
최종사용자별
일본
중국
인도
말레이시아
인도네시아
한국
호주
기타 아시아태평양
라틴아메리카
라틴아메리카의 인간 혈소판 용해액시장 : 유형별
라틴아메리카의 인간 혈소판 용해액시장 : 용도별
최종사용자별
멕시코
브라질
아르헨티나
기타 라틴아메리카
중동 및 아프리카
중동 및 아프리카의 인간 혈소판 용해액시장 : 유형별
중동 및 아프리카의 인간 혈소판 용해액시장 : 용도별
최종사용자별
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
기타 중동 및 아프리카
제9장 경쟁 구도
시장 주요 기업 : 분류
전략적 프레임워크
벤더 구도
전략 분류
최근 동향
제10장 기업 개요
Merck KGaA
Compass Biomedical, Inc.
PL BioScience GmbH
AventaCell BioMedical Corp.
Mill Creek Life Sciences
Stem Cell Technology, Inc.
ZenBio, Inc.
SCLAVO Diagnostics International
Lifescience Group Limited
Trinova Biochem GmbH
LSH
영문 목차
영문목차
The global human platelet lysate market size is expected to reach USD 78.48 million by 2034, according to a new study by Polaris Market Research. The report "Human Platelet Lysate Market Size, Share, Trends, & Industry Analysis Report: By Application (Research and Therapeutic), By Type, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Human Platelet Lysate (HPL) has emerged as a pivotal component in the field of biomedical research and regenerative medicine, revolutionizing cell culture techniques and therapeutic applications. This versatile product, derived from human blood platelets, offers numerous advantages over traditional cell culture supplements such as Fetal Bovine Serum (FBS). The growing demand for HPL can be attributed to several driving factors, including its safety, efficiency, and ethical considerations.
The human platelet lysate (HPL) market is growing due to scientific advancements and real-world healthcare needs. Governments across the world are investing heavily in regenerative medicine by providing funding, grants, and regulatory support. These efforts are encouraging scientists and companies to explore new treatments that rely on human platelet lysate to grow and expand cells safely and effectively. This support has helped build trust in the field and led to faster progress in stem cell therapy. Additionally, the rising number of chronic diseases such as Parkinson's disease, osteoarthritis, and hair loss (androgenetic alopecia) is driving the HPL market growth. These conditions are becoming more common due to aging populations and changing lifestyles. Many of them currently have limited treatment options, which is why doctors and researchers are turning to regenerative medicine. Platelet lysate is being used more often in these new therapies as it contains natural growth factors that help repair and regenerate damaged tissues.
The regulatory landscape has contributed to the growth of the HPL market. Regulatory bodies in many countries have been advocating for safer and more transparent research practices, which include the use of ethically sourced and safe cell culture supplements. HPL, with its favorable safety and ethical profiles, aligns with these regulatory requirements, easing the approval processes for clinical trials and therapeutic applications.
Human Platelet Lysate Market Report Highlights
By type, the heparin free based human platelet lysate segment dominated the human platelet lysate market share, due to its advantages in regulatory compliance, safety, and broader applicability in clinical and research settings. Heparin-free HPL has emerged as a critical component in cell culture and regenerative medicine, offering a serum-free alternative to traditional growth supplements.
By application, the research segment is expected to register a CAGR of 3.5% during the forecast period. The rapid growth is attributed to the growing use of human platelet lysate as a superior alternative to fetal bovine serum in cell culture research. It provides rich growth factors essential for expanding mesenchymal stem cells, immune cells, and other human-derived cells, making it ideal for preclinical and translational studies.
North America dominated the global human platelet lysate market revenue share in 2024. North America is a hub for stem cell research, encompassing pluripotent stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. HPL is employed to culture and expand these cells for research into developmental processes and therapeutic applications. In the US, stem cell culture serves as a fundamental element in the realms of regenerative medicine and biomedical research.
The human platelet lysate market in Europe is experiencing significant growth, owing to the region's strong emphasis on biomedical research, expanding regenerative medicine sector, and favorable regulatory landscape.
A few global key market players are Merck KGaA; Compass Biomedical Inc.; PL BioScience; AventaCell BioMedical Corp; Mill Creek Lifesciences LLC; Stem Cell Technologies Inc; Zen Bio, Inc.; Sclavo Diagnostics International Sr; Lifescience Group Limited; and Trinova Biochem GmbH.
Polaris Market Research has segmented the human platelet lysate market report on the basis of type, application, end use, and region:
By Type Outlook (Revenue, USD Million, 2020-2034)
Heparin Based HPL
Heparin Free HPL
By Application Outlook (Revenue, USD Million, 2020-2034)
Research
Therapeutic
By End Use Outlook (Revenue, USD Million, 2020-2034)
Pharmaceutical & Biotechnological Companies
Academic & Research Institutes
Others
By Regional Outlook (Revenue, USD Million, 2020-2034)
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Malaysia
Australia
Indonesia
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Table of Contents
Chapter 1. Introduction
1.1 Report Description
1.1.1 Objective of the Study
1.1.2 Market Scope
1.1.3 Assumptions
1.2 Stakeholders
Chapter 2. Research Methodology
2.1 Research Methodology
2.2 Research Scope and Assumptions
2.3 Information Procurement
2.3.1 Purchased Database
2.3.2 Internal Database
2.3.3 Secondary Sources
2.3.4 Third Party Perspective
2.3.5 Primary Research
2.4 Information Analysis
2.4.1 Data Analysis Models
2.5 Market Formulation and Data Visualization
2.6 Data Validation and Publishing (Secondary Sources)
Chapter 3. Executive Summary
Chapter 4. Market Insights
4.1 Human Platelet Lysate - Industry snapshot
4.2 Human Platelet Lysate Market - Value Chain Analysis
4.2.1 Human Platelet Lysate Market Dynamics
4.2.2 Drivers and Opportunities
4.2.2.1 Increasing in the research and development (R&D) activities of stem cell therapy by leading companies and governments
4.2.2.2 Increasing prevalence of chronic diseases such as Parkinson's disease, osteoarthritis, androgenetic alopecia and others
4.2.3 Restraints and Challenges
4.2.3.1 High cost and increased risk of transmission of infectious communicable diseases
4.3 Human Platelet Lysate Market - Porter's Five Forces
4.3.1 Threat of Substitutes: (Low)
4.3.2 Threat of New Entrants: (Low to Moderate)
4.3.3 Bargaining power of buyers: (Moderate)
4.3.4 Bargaining power of suppliers: (Moderate to High)
4.3.5 Competitive Rivalry: (Moderate to High)
4.4 Human Platelet Lysate Market - PESTLE Analysis
4.5 Covid-19 Impact Analysis & Industry Trends
Chapter 5. Human Platelet Lysate Market Assessment by Type
5.1 Introduction
5.2 Heparin Based Human Platelet Lysate
5.3 Heparin Free Based Human Platelet Lysate
Chapter 6. Human Platelet Lysate Market Assessment by Application
6.1 Introduction
6.2 Research
6.3 Therapeutic
Chapter 7. Human Platelet Lysate Market Assessment by End-User
7.1 Introduction
7.2 Pharmaceutical & Biotechnological Companies
7.3 Academic & Research Institutes
7.4 Others
Chapter 8. Human Platelet Lysate Market Assessment by Region
8.1 Introduction
8.2 Human Platelet Lysate Market - North America
8.2.1 North America Human Platelet Lysate, By Type
8.2.2 North America Human Platelet Lysate, By Application
8.2.3 North America Human Platelet Lysate Market, By End-User
8.2.4 Human Platelet Lysate Market - U.S.
8.2.4.1 U.S. Human Platelet Lysate, By Type
8.2.4.2 U.S. Human Platelet Lysate, By Application
8.2.4.3 U.S. Human Platelet Lysate Market, By End-User
8.2.5 Human Platelet Lysate Market - Canada
8.2.5.1 Canada Human Platelet Lysate, By Type
8.2.5.2 Canada Human Platelet Lysate, By Application
8.2.5.3 Canada Human Platelet Lysate Market, By End-User
8.3 Human Platelet Lysate Market - Europe
8.3.1 Europe Human Platelet Lysate, By Type
8.3.2 Europe Human Platelet Lysate, By Application
8.3.3 Europe Human Platelet Lysate Market, By End-User
8.3.4 Human Platelet Lysate Market - France
8.3.4.1 France Human Platelet Lysate, By Type
8.3.4.2 France Human Platelet Lysate, By Application
8.3.4.3 France Human Platelet Lysate Market, By End-User
8.3.5 Human Platelet Lysate Market - Germany
8.3.5.1 Germany Human Platelet Lysate, By Type
8.3.5.2 Germany Human Platelet Lysate, By Application
8.3.5.3 Germany Human Platelet Lysate Market, By End-User
8.3.6 Human Platelet Lysate Market - UK
8.3.6.1 U.K. Human Platelet Lysate, By Type
8.3.6.2 U.K. Human Platelet Lysate, By Application
8.3.6.3 U.K. Human Platelet Lysate Market, By End-User
8.3.7 Human Platelet Lysate Market - Italy
8.3.7.1 Italy Human Platelet Lysate, By Type
8.3.7.2 Italy Human Platelet Lysate, By Application
8.3.7.3 Italy Human Platelet Lysate Market, By End-User
8.3.8 Human Platelet Lysate Market - Netherlands
8.3.8.1 Netherlands Human Platelet Lysate, By Type
8.3.8.2 Netherlands Human Platelet Lysate, By Application
8.3.8.3 Netherlands Human Platelet Lysate Market, By End-User
8.3.9 Human Platelet Lysate Market - Spain
8.3.9.1 Spain Human Platelet Lysate, By Type
8.3.9.2 Spain Human Platelet Lysate, By Application
8.3.9.3 Spain Human Platelet Lysate Market, By End-User
8.3.10 Human Platelet Lysate Market - Russia
8.3.10.1 Russia Human Platelet Lysate, By Type
8.3.10.2 Russia Human Platelet Lysate, By Application
8.3.10.3 Russia Human Platelet Lysate Market, By End-User
8.3.11 Human Platelet Lysate Market - Rest of Europe
8.3.11.1 Rest of Europe Human Platelet Lysate, By Type
8.3.11.2 Rest of Europe Human Platelet Lysate, By Application
8.3.11.3 Rest of Europe Human Platelet Lysate Market, By End-User
8.4 Human Platelet Lysate Market - Asia Pacific
8.4.1 Asia Pacific Human Platelet Lysate, By Type
8.4.2 Asia Pacific Human Platelet Lysate, By Application
8.4.3 Asia Pacific Human Platelet Lysate Market, By End-User
8.4.4 Human Platelet Lysate Market - Japan
8.4.4.1 Japan Human Platelet Lysate, By Type
8.4.4.2 Japan Human Platelet Lysate, By Application
8.4.4.3 Japan Human Platelet Lysate Market, By End-User
8.4.5 Human Platelet Lysate Market - China
8.4.5.1 China Human Platelet Lysate, By Type
8.4.5.2 China Human Platelet Lysate, By Application
8.4.5.3 China Human Platelet Lysate Market, By End-User
8.4.6 Human Platelet Lysate Market - India
8.4.6.1 India Human Platelet Lysate, By Type
8.4.6.2 India Human Platelet Lysate, By Application
8.4.6.3 India Human Platelet Lysate Market, By End-User
8.4.7 Human Platelet Lysate Market - Malaysia
8.4.7.1 Malaysia Human Platelet Lysate, By Type
8.4.7.2 Malaysia Human Platelet Lysate, By Application
8.4.7.3 Malaysia Human Platelet Lysate Market, By End-User
8.4.8 Human Platelet Lysate Market - Indonesia
8.4.8.1 Indonesia Human Platelet Lysate, By Type
8.4.8.2 Indonesia Human Platelet Lysate, By Application
8.4.8.3 Indonesia Human Platelet Lysate Market, By End-User
8.4.9 Human Platelet Lysate Market - South Korea
8.4.9.1 South Korea Human Platelet Lysate, By Type
8.4.9.2 South Korea Human Platelet Lysate, By Application
8.4.9.3 South Korea Human Platelet Lysate Market, By End-User
8.4.10 Human Platelet Lysate Market - Australia
8.4.10.1 Australia Human Platelet Lysate, By Type
8.4.10.2 Australia Human Platelet Lysate, By Application
8.4.10.3 Australia Human Platelet Lysate Market, By End-User
8.4.11 Human Platelet Lysate Market - Rest of APAC
8.4.11.1 Rest of APAC Human Platelet Lysate, By Type
8.4.11.2 Rest of APAC Human Platelet Lysate, By Application
8.4.11.3 Rest of APAC Human Platelet Lysate Market, By End-User
8.5 Human Platelet Lysate Market - Latin America
8.5.1 Latin America Human Platelet Lysate, By Type
8.5.2 Latin America Human Platelet Lysate, By Application
8.5.3 Latin America Human Platelet Lysate Market, By End-User
8.5.4 Human Platelet Lysate Market - Mexico
8.5.4.1 Mexico Human Platelet Lysate, By Type
8.5.4.2 Mexico Human Platelet Lysate, By Application
8.5.4.3 Mexico Human Platelet Lysate Market, By End-User
8.5.5 Human Platelet Lysate Market - Brazil
8.5.5.1 Brazil Human Platelet Lysate, By Type
8.5.5.2 Brazil Human Platelet Lysate, By Application
8.5.5.3 Brazil Human Platelet Lysate Market, By End-User
8.5.6 Human Platelet Lysate Market - Argentina
8.5.6.1 Argentina Human Platelet Lysate, By Type
8.5.6.2 Argentina Human Platelet Lysate, By Application
8.5.6.3 Argentina Human Platelet Lysate Market, By End-User
8.5.7 Human Platelet Lysate Market - Rest of Latin America
8.5.7.1 Rest of Latin America Human Platelet Lysate, By Type
8.5.7.2 Rest of Latin America Human Platelet Lysate, By Application
8.5.7.3 Rest of Latin America Human Platelet Lysate Market, By End-User
8.6 Human Platelet Lysate Market - Middle East Africa
8.6.1 Middle East Africa Human Platelet Lysate, By Type
8.6.2 Middle East Africa Human Platelet Lysate, By Application
8.6.3 Middle East Africa Human Platelet Lysate Market, By End-User
8.6.4 Human Platelet Lysate Market - Saudi Arabia
8.6.4.1 Saudi Arabia Human Platelet Lysate, By Type
8.6.4.2 Saudi Arabia Human Platelet Lysate, By Application
8.6.4.3 Saudi Arabia Human Platelet Lysate Market, By End-User
8.6.5 Human Platelet Lysate Market - UAE
8.6.5.1 UAE Human Platelet Lysate, By Type
8.6.5.2 UAE Human Platelet Lysate, By Application
8.6.5.3 UAE Human Platelet Lysate Market, By End-User
8.6.6 Human Platelet Lysate Market - South Africa
8.6.6.1 South Africa Human Platelet Lysate, By Type
8.6.6.2 South Africa Human Platelet Lysate, By Application
8.6.6.3 South Africa Human Platelet Lysate Market, By End-User
8.6.7 Human Platelet Lysate Market - Rest of MEA
8.6.7.1 Rest of MEA Human Platelet Lysate, By Type
8.6.7.2 Rest of MEA Human Platelet Lysate, By Application
8.6.7.3 Rest of MEA Human Platelet Lysate Market, By End-User
